Table 1.
Characteristics of study patients by NPAR tertiles
| Characteristics | Tertile 1 (n = 266) < 21.58 |
Tertile 2 (n = 266) ≥ 21.58, < 26.77 |
Tertile 3 (n = 266) ≥ 26.77 |
p value |
|---|---|---|---|---|
| Age (years) | 67.50 (57.00–77.75) | 69.00 (58.00–79.00) | 73.00 (63.00–80.00) | 0.001 |
| Male, n (%) | 179 (67.29%) | 165 (62.03%) | 160 (60.15%) | 0.209 |
| Race, n (%) | 0.032 | |||
| White | 179 (67.29%) | 160 (60.15%) | 179 (67.29%) | |
| Black | 21 (7.89%) | 17 (6.39%) | 8 (3.01%) | |
| Other | 66 (24.81%) | 89 (33.46%) | 79 (29.70%) | |
| Heart rate (beats/minute) | 95.77 ± 25.54 | 101.57 ± 26.39 | 105.51 ± 24.40 | < 0.001 |
| MBP (mmHg) | 73.15 ± 34.18 | 67.20 ± 28.90 | 62.95 ± 29.72 | < 0.001 |
| Respiratory rate (beats/minute) | 24.24 ± 8.82 | 24.33 ± 9.81 | 25.47 ± 9.94 | 0.240 |
| Weight (kg) | 81.94 ± 19.31 | 79.13 ± 19.65 | 77.97 ± 19.72 | 0.017 |
| CAD | 192 (72.18%) | 207 (77.82%) | 146 (54.89%) | < 0.001 |
| Prior MI | 15 (5.64%) | 18 (6.77%) | 13 (4.89%) | 0.645 |
| AF | 67 (25.19%) | 80 (30.08%) | 100 (37.59%) | 0.008 |
| Hypertension | 136 (51.13%) | 118 (44.36%) | 91 (34.21%) | < 0.001 |
| Diabetes | 75 (28.20%) | 76 (28.57%) | 80 (30.08%) | 0.880 |
| CHF | 105 (39.47%) | 136 (51.13%) | 135 (50.75%) | 0.009 |
| CKD | 29 (10.90%) | 37 (13.91%) | 42 (15.79%) | 0.251 |
| Stroke | 6 (2.26%) | 10 (3.76%) | 14 (5.26%) | 0.190 |
| COPD | 4 (1.50%) | 2 (0.75%) | 8 (3.01%) | 0.131 |
| PTCA/PCI | 187 (70.30%) | 173 (65.04%) | 125 (46.99%) | < 0.001 |
| Laboratory parameters | ||||
| Neutrophil percentage (%) | 71.20 (61.35–78.95) | 84.00 (77.60–88.07) | 86.00 (80.85–89.77) | < 0.001 |
| Albumin (g/dL) | 3.80 (3.50–4.10) | 3.50 (3.20–3.70) | 2.70 (2.40–3.00) | < 0.001 |
| Hemoglobin (g/dL) | 13.35 (11.90–14.57) | 12.60 (11.10–14.10) | 11.35 (10.10–12.97) | < 0.001 |
| WBC (109/L) | 10.30 (7.50–13.80) | 12.50 (9.60–16.70) | 13.70 (10.10–17.50) | < 0.001 |
| PT (seconds) | 13.30 (12.50–14.00) | 13.70 (12.90–15.10) | 14.50 (13.30–16.88) | < 0.001 |
| Platelet (109/L) | 242.50 (188.25–301.75) | 252.00 (192.25–299.00) | 230.50 (170.25–302.75) | 0.113 |
| RDW (%) | 13.60 (13.10–14.50) | 13.70 (13.00–14.50) | 14.20 (13.30–15.60) | < 0.001 |
| Potassium (mmol/L) | 4.20 (3.90–4.60) | 4.10 (3.80–4.50) | 4.20 (3.80–4.70) | 0.216 |
| Sodium (mmol/L) | 139.00 (137.00–141.00) | 138.00 (135.25–141.00) | 139.00 (134.25–141.00) | 0.036 |
| Creatinine (mEq/L) | 1.10 (0.90–1.40) | 1.10 (0.90–1.40) | 1.20 (1.00–1.70) | < 0.001 |
| BUN (mg/dL) | 20.00 (15.00–28.00) | 21.00 (15.00–30.25) | 27.00 (18.50–43.50) | < 0.001 |
| ALT (U/L) | 30.21 (20.00–62.75) | 37.00 (21.00–68.75) | 42.33 (22.00–79.00) | 0.024 |
| AST (U/L) | 52.00 (26.25–124.63) | 74.50 (34.24–174.00) | 77.70 (38.00–196.37) | 0.001 |
| CK-peak (U/L) | 743.30 (292.70–1756.00) | 1088.50 (329.25–2427.20) | 702.00 (252.15–1983.00) | 0.052 |
| CK-MB-peak (U/L) | 53.00 (14.00–181.00) | 72.00 (13.00–227.50) | 37.00 (11.00–150.00) | 0.092 |
| Glucose (mg/dL) | 143.00 (115.25–191.75) | 148.00 (122.25–207.25) | 152.00 (119.25–213.75) | 0.254 |
| Scoring systems | ||||
| SAPS II | 34.00 (25.00–44.00) | 36.00 (28.00–48.00) | 43.00 (35.00–54.00) | < 0.001 |
| SOFA | 3.00 (1.00–2.00) | 4.00 (3.00–5.00) | 6.00 (7.00–10.00) | < 0.001 |
| Medication use, n (%) | ||||
| Aspirin | 214 (80.45%) | 221 (83.08%) | 172 (64.66%) | < 0.001 |
| Clopidogre | 132 (49.62%) | 148 (55.64%) | 117 (43.98%) | 0.027 |
| Metoprolol | 209 (78.57%) | 197 (74.06%) | 156 (58.65%) | < 0.001 |
| ACEI/ARBs | 156 (58.65%) | 171 (64.29%) | 100 (37.59%) | < 0.001 |
| Statin | 201 (75.56%) | 199 (74.81%) | 156 (58.65%) | < 0.001 |
| Urine output (ml/24 h) | 2116.00 (1424.00–3074.00) | 1825.00 (1090.00–2718.75) | 1377.50 (812.25–2275.25) | < 0.001 |
Continuous variables are presented as mean (SD) for normally distributed variables or median (interquartile range) for non-normally distributed variables, whereas categorical variables are presented as number (percentage)
MBP mean blood pressure, CAD coronary artery disease, prior MI prior myocardial infarction, AF atrial fibrillation, CHF chronic heart failure, CDK chronic kidney disease, COPD chronic obstructive pulmonary disease, PTCA/PCI percutaneous transluminal coronary angioplasty/percutaneous coronary intervention, WBC white blood cell, PT prothrombin time, RDW red cell distribution width, BUN blood urea nitrogen, ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, CK-MB MB isoenzyme of creatine kinase, SAPS II simplified acute physiology score II, SOFA sequential organ failure assessment score, ACEI/ARBs angiotensin-converting enzyme inhibitor/angiotensin receptor blockers